Unicycive Therapeutics, Inc. Annual Report - How They Did This Year

I’ve put together this guide to help you understand Unicycive Therapeutics’ performance. My goal is to turn complex filing information into plain English so you can decide if this company fits your investment strategy.

1. What does this company do?

Unicycive is a "clinical-stage" biotech company. They don't have products in stores yet; instead, they focus entirely on researching and testing new medicines to earn FDA approval. They have two main projects:

• Oxylanthanum Carbonate (OLC): A next-generation pill for patients with chronic kidney disease on dialysis. It is designed to be smaller and easier to swallow than current treatments, which may help patients stick to their medication.
• UNI-494: A drug currently in early testing designed to protect mitochondria. It aims to treat Acute Kidney Injury, a condition with no current FDA-approved therapies.

2. Financial performance

The company currently has no sales. For 2024, they reported a $36.7 million loss, compared to a $28.4 million loss in 2023. This increase reflects higher research costs as they prepare to launch OLC and run clinical trials.

As of late 2024, the company held about $18.2 million in cash. With monthly expenses ranging from $2.5 million to $3 million, they will need to raise additional capital to reach their June 2026 target date.

3. Major wins and challenges

The biggest story this year is the progress of their lead drug, OLC.

• The Setback: In June 2025, the FDA rejected their application. The issue was not the drug's safety or effectiveness, but rather manufacturing and quality control at a third-party facility.
• The Path Forward: Unicycive has addressed these issues and resubmitted their application. The FDA has accepted the new filing and set a target decision date of June 29, 2026. This date is the most critical event for the company’s future value.

4. Financial health and risks

The company is in a high-risk phase, relying entirely on outside funding since they have no revenue.

• Dilution: To fund operations, the company sells more shares. This reduces your ownership percentage in the company. If the stock price stays low, they must issue more shares to raise the same amount of cash, which impacts existing shareholders.
• The "All-or-Nothing" Risk: The company’s value depends almost entirely on OLC. If the FDA denies approval in 2026, the company may face significant financial strain, as they have no other products currently generating income.
• Manufacturing Reliance: Unicycive uses a third-party manufacturer. If that facility fails a future inspection, the company could face supply chain issues, even if the drug is approved.

5. Future outlook

All eyes are on June 2026. If the FDA approves OLC, Unicycive plans to transition from a research firm to a commercial business. They are building a lean team to keep costs low while preparing for a potential launch. They are also exploring new assets to add to their portfolio, though OLC remains the primary focus.

6. Should you invest?

This is a high-stakes, "all-or-nothing" investment. If the FDA approves OLC, the company gains a path to sustainability. If the FDA says "no," or if the company must sell more shares at poor prices to survive, shareholders could lose significant value. View this as a bet on regulatory approval and the company’s ability to manage its cash until mid-2026.

Investor Checklist:

• Monitor the June 29, 2026, FDA target date.
• Watch for updates on cash raises, as these will directly impact the value of your shares through dilution.
• Consider your risk tolerance: This investment is tied to a single regulatory outcome. Only invest capital you are comfortable potentially losing if the FDA decision does not go in the company's favor.